ALX Oncology's (ALXO) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of ALX Oncology (NASDAQ:ALXO - Free Report) in a research report report published on Friday morning,Benzinga reports. They currently have a $5.00 price target on the stock.

Several other equities research analysts have also issued reports on ALXO. UBS Group decreased their price target on shares of ALX Oncology from $4.00 to $2.20 and set a "buy" rating for the company in a research note on Monday, January 27th. Piper Sandler lifted their target price on shares of ALX Oncology from $8.00 to $9.00 and gave the stock an "overweight" rating in a research note on Thursday, March 6th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of ALX Oncology in a report on Friday, January 24th. Finally, Jefferies Financial Group upgraded ALX Oncology from a "hold" rating to a "buy" rating and lifted their price target for the company from $2.00 to $3.00 in a research report on Thursday, March 6th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, ALX Oncology presently has a consensus rating of "Moderate Buy" and a consensus target price of $4.14.

ALX Oncology Stock Performance

NASDAQ ALXO traded up $0.08 during trading hours on Friday, reaching $0.97. 870,119 shares of the company were exchanged, compared to its average volume of 979,178. The stock has a market capitalization of $51.34 million, a P/E ratio of -0.33 and a beta of 1.01. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. ALX Oncology has a 1 year low of $0.89 and a 1 year high of $17.83. The business's 50 day simple moving average is $1.37 and its 200-day simple moving average is $1.59.

Remove Ads

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Privium Fund Management B.V. increased its stake in ALX Oncology by 28.2% in the 3rd quarter. Privium Fund Management B.V. now owns 509,059 shares of the company's stock worth $926,000 after acquiring an additional 112,093 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of ALX Oncology during the third quarter worth about $469,000. GSA Capital Partners LLP purchased a new position in shares of ALX Oncology during the third quarter worth about $88,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of ALX Oncology by 207.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,042 shares of the company's stock worth $151,000 after buying an additional 56,028 shares during the last quarter. Finally, Walleye Capital LLC raised its position in ALX Oncology by 110.3% during the third quarter. Walleye Capital LLC now owns 230,875 shares of the company's stock valued at $420,000 after purchasing an additional 121,113 shares in the last quarter. Institutional investors own 97.97% of the company's stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.